含 30 微克炔雌醇和 3.0 毫克屈螺酮的复方口服避孕药不会损害血管内皮依赖性血管舒张功能。
A combined oral contraceptive containing 30 mcg ethinyl estradiol and 3.0 mg drospirenone does not impair endothelium-dependent vasodilation.
机构信息
Department of Human Physiology, University of Oregon, Eugene, OR 97403, USA.
出版信息
Contraception. 2010 Oct;82(4):366-72. doi: 10.1016/j.contraception.2010.03.009. Epub 2010 Apr 27.
BACKGROUND
Ethinyl estradiol (EE) increases endothelium-dependent vasodilation in young women, but certain progestins paired with EE in combination oral contraceptive pills (OCPs) have been shown to antagonize the vasodilatory effects of EE. Therefore, the purpose of this study was to investigate how endothelial function, serum biomarkers and resting blood pressures change across an OCP cycle in women using a monophasic OCP formulation containing the progestin drospirenone.
STUDY DESIGN
Twelve women were studied during two hormone phases of their OCP cycle: once at the end of 3 weeks of active pills (30 mcg EE and 3.0 mg drospirenone) and once at the end of a week of placebo pills (no exogenous hormones)
RESULTS
Endothelium-dependent vasodilation was greater during the active phase compared to the placebo phase (p<.001). In contrast, there was no difference in endothelium-independent dilation between hormone phases.
CONCLUSION
These data suggest that the combination of 30 mcg EE and 3.0 mg drospirenone used in the active phase of this OCP increases endothelium-dependent vasodilation compared to a placebo phase.
背景
炔雌醇（EE）可增加年轻女性的内皮依赖性血管舒张，但某些孕激素与 EE 联合用于复方口服避孕药（OCP）时，已被证明会拮抗 EE 的血管舒张作用。因此，本研究的目的是调查使用含有孕激素屈螺酮的单相 OCP 制剂的女性在 OCP 周期中，内皮功能、血清生物标志物和静息血压如何随 OCP 周期变化。
研究设计
12 名女性在 OCP 周期的两个激素阶段接受研究：一次在服用活性药物（30 mcg EE 和 3.0 mg 屈螺酮）结束后的 3 周，一次在服用安慰剂（无外源性激素）结束后的一周。
结果
与安慰剂阶段相比，活性阶段的内皮依赖性血管舒张更大（p<.001）。相比之下，激素阶段之间的非内皮依赖性扩张没有差异。
结论
这些数据表明，在这种 OCP 的活性阶段使用的 30 mcg EE 和 3.0 mg 屈螺酮的组合与安慰剂阶段相比，增加了内皮依赖性血管舒张。
Zotero 插件